CBD and Pain: A Comprehensive Analysis of the Potential Benefits and Current Research


Cannabidiol (CBD) is a non-psychoactive compound derived from the cannabis plant. In recent years, interest in CBD as a potential pain management option has grown significantly. This paper provides an in-depth analysis of current research on CBD and its potential applications for pain management. A review of the literature revealed that while there is preliminary evidence suggesting CBD may be effective in managing various types of pain, additional research is required to establish the extent of its effectiveness and identify optimal dosing strategies.

What this means for you

We explored CBD, which is a compound found in the cannabis plant, and its potential for helping people with pain management. Our aim was to gain a deeper understanding of whether CBD can be a useful option for pain relief and how it works. Although we found some promising results, more research is needed to confirm its effectiveness.


Pain is a complex and multifaceted phenomenon that affects millions of people worldwide, often leading to reduced quality of life and limitations in daily functioning (Breivik et al., 2006). Traditional pain management approaches, such as pharmaceuticals and invasive procedures, may not always provide adequate relief and can be associated with significant side effects (Borrelli et al., 2013). As a result, there is a growing interest in alternative and complementary treatments, including the use of cannabinoids like cannabidiol (CBD) for pain management (Mücke et al., 2018).

Cannabidiol is a non-psychoactive compound found in the cannabis plant. Unlike its psychoactive counterpart, tetrahydrocannabinol (THC), CBD does not produce a “high” or euphoria (Mechoulam et al., 2007). Instead, CBD has been investigated for its potential therapeutic properties, including its analgesic (pain-relieving) effects (Russo, 2008). This paper aims to provide an in-depth analysis of current research on CBD and its potential applications for pain management.

What this means for you

Pain affects a large number of people, and it can significantly impact their quality of life. Traditional pain management methods may not always provide enough relief and can come with side effects. This is why we are interested in alternative options, like CBD, to see if they could offer a better solution for people struggling with pain.


A comprehensive literature review was conducted using PubMed, Web of Science, and Google Scholar databases. Articles published in English between 2000 and 2021 were considered. Search terms included “cannabidiol,” “CBD,” “pain,” “analgesia,” “inflammation,” and “chronic pain.” Relevant articles were reviewed, and the findings were synthesized to provide a comprehensive understanding of the current state of research on CBD and pain.

What this means for you

To get a comprehensive understanding of what has been researched about CBD and pain, we went through a wide range of scientific articles published from 2000 to 2021. This allowed us to collect all the essential information and present you with a clear overview of the current knowledge on this topic.

Results and Discussion

Mechanism of action

CBD is thought to exert its analgesic effects through a variety of mechanisms, including interactions with the endocannabinoid system (ECS), modulation of the transient receptor potential vanilloid 1 (TRPV1), and inhibition of fatty acid amide hydrolase (FAAH) (Russo, 2008; Pisanti et al., 2017). The ECS plays a crucial role in pain modulation, and CBD has been shown to enhance the activity of endogenous cannabinoids, such as anandamide (AEA), which can produce analgesic effects (Pacher et al., 2006). CBD has also been shown to modulate the activity of other receptors involved in pain perception, including serotonin, adenosine, and opioid receptors (Russo, 2008; Pisanti et al., 2017).

What this means for you

CBD appears to help with pain through multiple pathways, including interacting with the body’s endocannabinoid system, which is crucial for pain management. In simpler terms, CBD could enhance your body’s natural pain-relieving processes, making them more effective.

Preclinical studies

Preclinical studies using animal models have provided evidence for the analgesic effects of CBD. In rodent models of inflammatory and neuropathic pain, CBD has been shown to reduce pain-related behaviors and decrease inflammation (Costa et al., 2007; King et al., 2017). In addition, CBD has demonstrated efficacy in reducing pain and inflammation in models of osteoarthritis, multiple sclerosis, and diabetic neuropathy (Philpott et al., 2017; Giacoppo et al., 2015; Toth et al., 2010). However, it is essential to recognize that animal studies do not always translate directly to human outcomes, and more research is needed to confirm these findings in human populations.

What this means for you

Animal studies have shown that CBD could potentially help with pain and inflammation, which is a promising finding. However, we should keep in mind that results from animal studies don’t always translate directly to humans, and more research is needed to confirm these effects in people.

Human studies

Clinical trials examining the effects of CBD on pain are limited but have yielded promising results. A review by Mücke et al. (2018) found that CBD was effective in reducing pain and improving sleep quality in patients with chronic pain conditions, including fibromyalgia, neuropathic pain, and arthritis. However, the authors noted that most studies included small sample sizes and varied in their methodology, making it difficult to draw definitive conclusions.

A recent systematic review and meta-analysis by Vučković et al. (2018) analyzed the efficacy of cannabinoids, including CBD, in treating chronic pain. The review found that CBD was more effective than placebo in reducing pain, but the overall quality of evidence was rated as low due to the limited number of high-quality studies available. The authors emphasized the need for additional well-designed clinical trials to confirm the analgesic effects of CBD.

Several other clinical trials have investigated the effects of CBD on specific pain conditions. For example, a randomized, double-blind, placebo-controlled trial by Blake et al. (2006) found that a cannabis extract containing both THC and CBD was effective in reducing pain and improving sleep in patients with rheumatoid arthritis. A more recent study by Xu et al. (2020) found that CBD was effective in reducing pain and improving functional outcomes in patients with chronic low back pain.

Furthermore, a study by Johnson et al. (2010) reported that CBD could reduce pain and improve quality of life in patients with intractable cancer pain. The study found that a cannabis extract containing both THC and CBD was more effective than THC alone or a placebo in reducing pain. However, the study was limited by its small sample size, and more research is needed to confirm these findings.

What this means for you

There have been a few clinical trials investigating CBD’s effects on pain in humans, and the results seem positive. However, these studies often involved small numbers of participants, so we still need more extensive research to be confident that CBD is truly beneficial for pain relief in people.

Safety and side effects

CBD is generally considered to be well-tolerated with a favorable safety profile (Iffland & Grotenhermen, 2017). Common side effects of CBD are mild and may include drowsiness, dry mouth, and gastrointestinal disturbances (MacCallum & Russo, 2018). However, interactions with other medications and potential long-term effects of CBD use require further investigation.

Some studies have reported more severe side effects, such as liver injury and drug interactions, particularly when CBD is taken in high doses or in combination with other medications (Ewing et al., 2020; Brown & Winterstein, 2019). Additionally, CBD’s effects on pregnant or breastfeeding women, children, and individuals with pre-existing liver or kidney conditions remain understudied and warrant further investigation.

What this means for you

CBD is generally considered safe, but it can come with some mild side effects, such as drowsiness, dry mouth, or digestive issues. More research is needed to fully understand how CBD might interact with other medications or what the long-term effects might be, especially for specific populations like pregnant women, children, or people with pre-existing health conditions.

Dosage and administration

Determining the optimal dose of CBD for pain management remains a challenge due to the variability in individual responses and the lack of standardized dosing guidelines. Clinical trials have used a wide range of CBD doses, from as low as 1 mg/kg per day to as high as 600 mg/day (Mücke et al., 2018; Vučković et al., 2018). Further research is needed to establish standardized dosing protocols and to identify the most effective routes of administration (e.g., oral, sublingual, or topical).

What this means for you

Determining the ideal amount of CBD for pain management is challenging because everyone’s response can be different, and there aren’t any standardized guidelines. More research is required to help establish the best practices for people to use CBD for pain relief, including the most effective dosing and methods of administration.

Legal and regulatory considerations

The legal and regulatory status of CBD varies by country and jurisdiction. In the United States, the 2018 Farm Bill legalized the cultivation of hemp, which is defined as cannabis containing less than 0.3% THC. This has led to an increase in the availability of CBD products derived from hemp. However, the U.S. Food and Drug Administration (FDA) has approved only one CBD product, Epidiolex, for the treatment of certain rare forms of epilepsy (Epidiolex, 2020). The FDA has not yet approved CBD for the treatment of pain or any other medical conditions, and the agency continues to regulate CBD products to ensure their safety and efficacy. Consumers should be cautious when purchasing CBD products and consult with a healthcare professional to determine the appropriate use of CBD for pain management.

In other countries, the legal status of CBD may differ, and it is important for individuals to familiarize themselves with local regulations governing the use of CBD products.

What this means for you

The legal status of CBD can vary depending on where you live. In the United States, CBD products derived from hemp are more widely available, but the FDA has only approved one CBD product for treating specific epilepsy conditions. It’s crucial to exercise caution when purchasing CBD products. Only purchase from trusted sellers, and consult a healthcare professional


Current research on CBD and pain management is still in its early stages. Preliminary evidence suggests that CBD may be effective in managing various types of pain, including inflammatory and neuropathic pain. However, additional well-designed clinical trials are needed to confirm these findings and to establish optimal dosing strategies. Additionally, further research should focus on elucidating the mechanisms underlying the analgesic effects of CBD and investigating the safety and potential long-term effects of CBD use.

Legal and regulatory considerations surrounding CBD should also be taken into account when considering its use for pain management. Consumers should be cautious when purchasing CBD products and consult with a healthcare professional to determine the appropriate use of CBD for their specific needs.

As the body of evidence regarding CBD’s potential analgesic effects continues to grow, it is essential for healthcare professionals, researchers, and policymakers to stay informed about the latest developments in this rapidly evolving field. This will ensure that patients can access safe, effective, and evidence-based treatments for their pain management needs.

What this means for you

Early research on CBD and pain management shows potential, but we still need more studies to better understand its effectiveness and how to use it optimally. Additionally, it’s essential to consider the legal and regulatory aspects of CBD when thinking about using it for pain relief. As more research becomes available, we will be better equipped to make informed decisions about whether CBD is a viable option for managing pain.

Works Cited

Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006). Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. European Journal of Pain, 10(4), 287–333.

Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., … & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306-1316.

Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology, 556(1-3), 75-83.

Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139-154.

King, K. M., Myers, A. M., Soroka-Monzo, A. J., Tuma, R. F., Tallarida, R. J., Walker, E. A., & Ward, S. J. (2017). Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. British Journal of Pharmacology, 174(17), 2832-2841.

MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12-19.

Mechoulam, R., Peters, M., Murillo-Rodriguez, E., & Hanuš, L. O. (2007). Cannabidiol–recent advances. Chemistry & Biodiversity, 4(8), 1678-1692.

Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2018(3), CD012182.

Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462.

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., … & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133-150.

Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4(1), 245-259.

Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018). Cannabinoids and pain: New insights from old molecules. Frontiers in Pharmacology, 9, 1259.


Select your location